The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000447358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
25/03/2026
Date registered
Help: Date registered
10/04/2026
Date last updated
Help: Date last updated
10/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
10/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
ACE Trial: Assessing Cyproheptadine and Endep for treatment of vestibular migraine. A Randomised Controlled Trial
Scientific title
ACE Trial: Assessing Cyproheptadine and Endep for treatment of vestibular migraine. A Randomised Controlled Trial in diagnosed Adult patients
Additional trial identifiers [1] 314994 0
None
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Vestibular migraine 341109 0
Condition category
Condition code
Ear 337224 337224 0 0
Other ear disorders
Neurological 337466 337466 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Intervention arm 1: Cyproheptadine orally 2mg nocte for 2 nights, then 4mg orally nocte ongoing for 11 weeks and 5 days
Intervention arm 2: Amitriptyline 5mg orally nocte for 2 nights, 10mg orally nocte ongoing for 11 weeks and 5 days
Participants will only be asked to take one drug.
Adherence to study medication will be assessed using multiple measures, with a medication diary as the primary tool. Participants will be provided with a diary to record daily medication use, including doses taken, missed doses, and any treatment interruptions.

Participants will be instructed to return all medication packaging, including unused tablets, at each study visit. Tablet counts will be performed and compared with diary entries to estimate adherence as the proportion of prescribed doses taken.

At each follow-up visit, participants will be asked about adherence, including missed doses and reasons for non-adherence, and this will be recorded in the case report form. The clinical trials pharmacy will maintain investigational product accountability logs documenting dispensing, return, and reconciliation of study medication, which will be cross-checked against diary records and tablet counts.
Any treatment interruptions, discontinuation, or adherence concerns will be documented and considered in the analysis.
Intervention code [1] 333474 0
Treatment: Drugs
Description of the comparator or control
Folic acid 250microg orally nocte for 2 nights then 500microg orally nocte for 11 weeks and 5 days
Control group
Active

Outcomes
Primary outcome [1] 344742 0
Vestibular migraine symptoms
Timepoint [1] 344742 0
Baseline (Day the patient is enrolled in the trial, prior to commencing treatment) 6 weeks and 12 weeks after commencing treatment
Primary outcome [2] 344743 0
Treatment efficacy of cyproheptadine versus amitriptyline for the treatment of vestibular migraine
Timepoint [2] 344743 0
Baseline assessment, 6 and 12 weeks after commencing treatment
Secondary outcome [1] 459068 0
Side Effect Profiles of Cyproheptadine versus Amitriptyline
Timepoint [1] 459068 0
6 and 12 weeks after commencing treatment

Eligibility
Key inclusion criteria
1. Patients who are diagnosed in vestibular clinic with vestibular migraine per the Bárány Society diagnostic criteria for vestibular migraine AND including the following:
a. Patients who have had an audiogram that excludes Meniere’s Disease
b. In the case of unilateral hearing loss confirmed on audiogram, patients who have had an MRI to exclude a central cause for symptoms or retrocochlear pathology
c. Patients who have had an Oculomotor exam by the vestibular physiotherapist
d. Patients who have had a Video Head Impulse Test (VHIT) by the vestibular physiotherapist
2. Diagnosis over the course of the clinical trial
3. Age 18 years old and above
4. All genders
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Patients who are currently receiving treatment for vestibular migraine
2. Patients who are pregnant
3. Patients with cognitive impairment or who are legally not able to provide consent
4. Patients with substance abuse, especially alcohol due to the risk of central nervous system depressant effects with the medications
5. Patients on selective serotonin reuptake inhibitors (SSRIs) due to drug interaction with amitriptyline

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
pre-prepared sealed envelopes
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment postcode(s) [1] 45571 0
4350 - South Toowoomba

Funding & Sponsors
Funding source category [1] 319545 0
Charities/Societies/Foundations
Name [1] 319545 0
Toowoomba Hospital Foundation
Country [1] 319545 0
Australia
Primary sponsor type
Individual
Name
Lauren Byrnes - Darling Downs Health
Address
Country
Australia
Secondary sponsor category [1] 322050 0
None
Name [1] 322050 0
Address [1] 322050 0
Country [1] 322050 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 318121 0
Darling Downs Hospital and Health Service Human Research Ethics Committee
Ethics committee address [1] 318121 0
Ethics committee country [1] 318121 0
Australia
Date submitted for ethics approval [1] 318121 0
25/03/2026
Approval date [1] 318121 0
26/03/2026
Ethics approval number [1] 318121 0
HREC/2026/QTDD/121201

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 143182 0
Dr Lauren Byrnes
Address 143182 0
Toowoomba Base Hospital, Pechey St, Toowoomba QLD 4350
Country 143182 0
Australia
Phone 143182 0
+61 746166000
Fax 143182 0
Email 143182 0
Contact person for public queries
Name 143183 0
Lauren Byrnes
Address 143183 0
Toowoomba Base Hospital, Pechey St, Toowoomba QLD 4350
Country 143183 0
Australia
Phone 143183 0
+61 746166000
Fax 143183 0
Email 143183 0
Contact person for scientific queries
Name 143184 0
Lauren Byrnes
Address 143184 0
Toowoomba Base Hospital, Pechey St, Toowoomba QLD 4350
Country 143184 0
Australia
Phone 143184 0
+61 746166000
Fax 143184 0
Email 143184 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Informed consent form    Appendix 12 - Patient Information and Consent Form.docx


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.